Efferon OÜ has raised $4.8M to keep building out its line of blood purification devices. The company makes multimodal hemoadsorption products - Efferon LPS and Efferon NEO - designed to pull bacterial endotoxins and excess cytokines straight out of the bloodstream, targeting sepsis, septic shock, and cytokine release syndrome in adults and pediatric patients.
The mission behind the devices is blunt: sepsis kills roughly 20 million people a year, and Efferon frames its work as cutting into that number. The company develops and manufactures the hardware itself.
